Genetic Baldness Test Complies With The European Directive On In Vitro Diagnostic Medical Devices

Main Category: Dermatology
Also Included In: Medical Devices / Diagnostics
Article Date: 09 Oct 2009 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

The HairDX Genetic Test for Hair Loss, the world's first genetic baldness (Androgenetic Alopecia) test, is now available as a CE Marked product under the European In Vitro Diagnostic Directive.

The announcement was made at the 18th European Academy of Dermatology and Venereology (EADV) Congress in Berlin today by pharmacogenomics research and development innovator PharmaGenoma, Inc. and its subsidiary HairDX Europe, pioneers of genetic tests for predicting the risk of male and female hair loss.

CE Marking is required for certain product groups to indicate conformity with the essential requirements set out in European Directives. The HairDX Genetic Test For Hair Loss complies with the essential requirements of the European IVD Directive.

HairDX's easy to use genetic test provides a genetic analysis of a man's or woman's likelihood of developing Androgenetic Alopecia, the most common type of hair loss.

"We are excited to extend our innovative line of genetics products to dermatologists in Europe," says Andy Goren, CEO of HairDX, LLC. "Our leadership in research and development enables dermatologists to help patients determine proper treatments."

About HairDX Europe

HairDX Europe is part of PharmaGenoma B.V.B.A. The company is located in Hasselt, Belgium, near Brussels, and the German and Dutch borders. PharmaGenoma B.V.B.A. is setup to support logistics and sales/marketing activities to existing distribution networks for in Europe, Middle-East and Africa, and to expand current distribution network to more countries.

Source
HairDX, LLC.